The winners of the EIT Health Catapult 2023 competition were announced at the Bits & Pretzels Conference, where Immunyx, a developer of immune modulating therapies for neutrophil based diseases, won in the biotech category.
The competition, an initiative by EIT Health, aims to accelerate the growth of European health start-ups by providing them with access to experts and investors.
Now in its seventh year, Catapult has already supported more than 200 start-ups, with a community of more than 400 investors and 2,500 healthcare professionals backing the programme. Catapult is part of EIT Health’s extensive portfolio of initiatives aimed at elevating a fresh generation of companies capable of delivering transformative solutions to health challenges faced by Europe’s citizens.
Immunyx CEO, Seth Salpeter, said that the company are developing new types of drugs to modulate the immune system, focusing on white blood cells that battle infection in persistent diseases.
Spanish start-up, Time is Brain, won in the MedTech category, and German start-up, Deepeye, won in the Digital Health category.
Magda Krakowiak, Director of Business Creation, EIT Health, said: “Each year, the EIT Health Catapult unearths some of Europe’s most inspiring start-ups, and the 2023 competition was no exception. The reveal of the winners at yesterday’s finals at the Bits & Pretzels Conference marked another milestone in European healthcare innovation. We stand ready to support these start-ups in their mission to transform healthcare.”
